For research use only. Not for therapeutic Use.
PLX73086（Cat No.:I034892）is an investigational small molecule drug developed by Plexxikon, primarily being studied for its potential in treating cancer, particularly melanoma and other solid tumors. It functions as a selective inhibitor of the oncogenic BRAF V600E mutation, which is common in melanoma and drives cancer cell growth. By blocking this mutated protein, PLX73086 aims to inhibit tumor proliferation and improve patient outcomes. While early preclinical studies have shown promising results, further clinical trials are required to assess its safety, efficacy, and potential for combination with other cancer therapies.
| Catalog Number | I034892 |
| Synonyms | AC708; AC-708; AC 708; PLX73086; PLX-73086; PLX 73086; |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
